We are live on ! Find out more
GLSI icon

Greenwich LifeSciences
GLSI

24 hedge funds and large institutions have $4.75M invested in Greenwich LifeSciences in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

4% more funds holding

Funds holding: 23 → 24 (+1)

0.71% less ownership

Funds ownership: 4.89% → 4.18% (-0.71%)

22% less capital invested

Capital invested by funds: $6.06M → $4.75M (-$1.31M)

56% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 9

Holders
24
Holders Change
+1
Holders Change %
+4.35%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
9
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
+$117K
2
Squarepoint
Squarepoint
New York
+$103K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$57.8K
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$12.3K
5
TRCT
Tower Research Capital (TRC)
New York
+$639

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$585K
2
Renaissance Technologies
Renaissance Technologies
New York
-$234K
3
Millennium Management
Millennium Management
New York
-$152K
4
HF
HRT Financial
New York
-$97K
5
Ameriprise
Ameriprise
Minnesota
-$45K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.94M -$585K -62,262 -22%
Ameriprise
2
Ameriprise
Minnesota
$560K -$45K -4,788 -7%
BlackRock
3
BlackRock
New York
$495K -$14.9K -1,585 -3%
Renaissance Technologies
4
Renaissance Technologies
New York
$480K -$234K -24,902 -31%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$408K +$57.8K +6,159 +15%
GCP
6
GSA Capital Partners
United Kingdom
$405K +$117K +12,441 +37%
Millennium Management
7
Millennium Management
New York
$169K -$152K -16,193 -46%
State Street
8
State Street
Massachusetts
$115K – – –
Squarepoint
9
Squarepoint
New York
$97K +$103K +10,970 New
Bank of America
10
Bank of America
North Carolina
$29.8K -$15.9K -1,691 -33%
NFSG
11
Newbridge Financial Services Group
Florida
$13.3K – – –
Qube Research & Technologies (QRT)
12
Qube Research & Technologies (QRT)
United Kingdom
$11.6K +$12.3K +1,310 New
TRCT
13
Tower Research Capital (TRC)
New York
$11.5K +$639 +68 +6%
FCMT
14
Founders Capital Management (Texas)
Texas
$4.42K – – –
Morgan Stanley
15
Morgan Stanley
New York
$2.48K -$4.48K -477 -63%
Fidelity Investments
16
Fidelity Investments
Massachusetts
$822 – – –
GWM
17
Geneos Wealth Management
Colorado
$778 – – –
NSIM
18
North Star Investment Management
Illinois
$451 – – –
AF
19
Advisornet Financial
Minnesota
$442 – – –
Osaic Holdings
20
Osaic Holdings
Arizona
$442 – – –
Wells Fargo
21
Wells Fargo
California
$336 +$122 +13 +52%
JP Morgan Chase
22
JP Morgan Chase
New York
$35 – – –
UBS Group
23
UBS Group
Switzerland
$9 -$2.13K -227 -100%
HF
24
HRT Financial
New York
– -$97K -10,136 Closed
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
– -$911 -97 -92%

GLSI Hedge Fund Activity: Q3 2023 in Review

24 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Greenwich LifeSciences (GLSI) for Q3 2023, worth a combined $4.75M — down 22% from $6.06M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new GLSI positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 9 trimmed.

The largest buyer was GSA Capital Partners, adding an estimated $117K. The largest seller was Vanguard Group, cutting an estimated $585K.

  • 24 institutional investors held Greenwich LifeSciences (GLSI) as of Q3 2023, up from 23 in Q2 2023.
  • Funds reported $4.75M of Greenwich LifeSciences stock for Q3 2023, down 22% quarter-over-quarter.
  • 2 funds opened new Greenwich LifeSciences positions in Q3 2023 and 1 closed out, a net change of +1 holder.
  • The largest Greenwich LifeSciences buyer in Q3 2023 was GSA Capital Partners, an estimated $117K added.
  • The largest Greenwich LifeSciences seller in Q3 2023 was Vanguard Group, an estimated $585K sold.

Based on aggregated 13F filings for Q3 2023.